AIMS: To determine if regional gray matter volume (GMV) differences in middle-aged adults with and without type-1 diabetes (T1D) are localized in areas most vulnerable to aging, e.g. fronto-subcortical networks; and if these differences are explained by cardiovascular risk factors and diabetes complications. METHODS: Regional GMV was computed using 3T MRI of 104 adults with a childhood onset of T1D (mean age: 49±7 and duration: 41±6years) and 151 adults without diabetes (mean age: 40±6). A Bonferroni threshold (n=45, p≤0.001) was applied to account for multiple between-group comparisons and analyses were repeated in an age- and gender-matched subset of participants with T1D and controls (n=44 in each group, mean age [SD] and range: 44.0, [4.3], 17.4 and 44.6 [4.3], 17.0, respectively). RESULTS: Compared to controls, T1D patients had smaller GMV in the frontal lobe (6% to 19% smaller) and adjacent supramarginal and postcentral gyri (8% to 13% smaller). Between-group differences were independent of age, waist circumference, systolic blood pressure, fasting total cholesterol and smoking status and were similar in sensitivity analyses restricted to age- and gender-matched participants. Associations between GMV and diabetes complications were not significant. CONCLUSIONS: These findings extend the notion of accelerated brain aging in T1D to middle-aged adults. The pathophysiology of frontal gray matter atrophy and its impact on future development of disability and dementia need further study, especially as middle-aged T1D patients progress to older age.
AIMS: To determine if regional gray matter volume (GMV) differences in middle-aged adults with and without type-1 diabetes (T1D) are localized in areas most vulnerable to aging, e.g. fronto-subcortical networks; and if these differences are explained by cardiovascular risk factors and diabetes complications. METHODS: Regional GMV was computed using 3T MRI of 104 adults with a childhood onset of T1D (mean age: 49±7 and duration: 41±6years) and 151 adults without diabetes (mean age: 40±6). A Bonferroni threshold (n=45, p≤0.001) was applied to account for multiple between-group comparisons and analyses were repeated in an age- and gender-matched subset of participants with T1D and controls (n=44 in each group, mean age [SD] and range: 44.0, [4.3], 17.4 and 44.6 [4.3], 17.0, respectively). RESULTS: Compared to controls, T1D patients had smaller GMV in the frontal lobe (6% to 19% smaller) and adjacent supramarginal and postcentral gyri (8% to 13% smaller). Between-group differences were independent of age, waist circumference, systolic blood pressure, fasting total cholesterol and smoking status and were similar in sensitivity analyses restricted to age- and gender-matched participants. Associations between GMV and diabetes complications were not significant. CONCLUSIONS: These findings extend the notion of accelerated brain aging in T1D to middle-aged adults. The pathophysiology of frontal gray matter atrophy and its impact on future development of disability and dementia need further study, especially as middle-aged T1D patients progress to older age.
Authors: Susan M Resnick; Dzung L Pham; Michael A Kraut; Alan B Zonderman; Christos Davatzikos Journal: J Neurosci Date: 2003-04-15 Impact factor: 6.167
Authors: Gabriel Ziegler; Robert Dahnke; Lutz Jäncke; Rachel Aine Yotter; Arne May; Christian Gaser Journal: Hum Brain Mapp Date: 2011-09-06 Impact factor: 5.038
Authors: A M Wessels; S Simsek; P L Remijnse; D J Veltman; G J Biessels; F Barkhof; P Scheltens; F J Snoek; R J Heine; S A R B Rombouts Journal: Diabetologia Date: 2006-05-16 Impact factor: 10.122
Authors: Gail Musen; In Kyoon Lyoo; Caitlin R Sparks; Katie Weinger; Jaeuk Hwang; Christopher M Ryan; David C Jimerson; John Hennen; Perry F Renshaw; Alan M Jacobson Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: Margaret S Ho; Narelle J Weller; F Jay Ives; Christine L Carne; Katherine Murray; Rohan I Vanden Driesen; Thai P Nguyen; Peter D Robins; Max Bulsara; Elizabeth A Davis; Timothy W Jones Journal: J Pediatr Date: 2008-04-28 Impact factor: 4.406
Authors: Gaby S Pell; Ashleigh Lin; R Mark Wellard; George A Werther; Fergus J Cameron; Sue J Finch; Jennifer Papoutsis; Elisabeth A Northam Journal: Diabetes Care Date: 2012-02-01 Impact factor: 19.112
Authors: Karen A Nunley; Christopher M Ryan; Howard J Aizenstein; J Richard Jennings; Rebecca L MacCloud; Trevor J Orchard; Caterina Rosano Journal: Psychosom Med Date: 2017-06 Impact factor: 4.312
Authors: Christopher M Ryan; Barbara E K Klein; Kristine E Lee; Karen J Cruickshanks; Ronald Klein Journal: J Diabetes Complications Date: 2016-08-14 Impact factor: 2.852
Authors: Pavel Filip; Petr Bednarik; Lynn E Eberly; Amir Moheet; Alena Svatkova; Heidi Grohn; Anjali F Kumar; Elizabeth R Seaquist; Silvia Mangia Journal: Neuroradiology Date: 2022-01-06 Impact factor: 2.804
Authors: Eelco van Duinkerken; Richard G Ijzerman; Martin Klein; Annette C Moll; Frank J Snoek; Philip Scheltens; Petra J W Pouwels; Frederik Barkhof; Michaela Diamant; Betty M Tijms Journal: Hum Brain Mapp Date: 2015-12-23 Impact factor: 5.038
Authors: Karen A Nunley; Regina L Leckie; Trevor J Orchard; Tina Costacou; Howard J Aizenstein; J Richard Jennings; Kirk I Erickson; Caterina Rosano Journal: Neurology Date: 2017-03-10 Impact factor: 9.910
Authors: Paul K Mazaika; Stuart A Weinzimer; Nelly Mauras; Bruce Buckingham; Neil H White; Eva Tsalikian; Tamara Hershey; Allison Cato; Tandy Aye; Larry Fox; Darrell M Wilson; Michael J Tansey; William Tamborlane; Daniel Peng; Mira Raman; Matthew Marzelli; Allan L Reiss Journal: Diabetes Date: 2015-10-28 Impact factor: 9.337